bristol myers squibb astrazeneca financial times opdivo qvantig

AstraZeneca negotiates merger with Bristol Myers Squibb

Reliability 83 · very high3 h agoAugust 3, 2026

Center-left1
Center2
Center-right1
Agency1

5 sources5 independent voices

no rewrites detected — all voices distinct

4 countries · 4 languagesLeft & right

Summary

BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn. AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn. Both companies have been assessing the possible alliance in recent months and contacts may lead to an agreement , although it is also possible that the project will not advance, the FT added.

Furthermore, AstraZeneca has grown to become a “giant” in the pharmaceutical sector with a leading portfolio of oncology medicines, but Bristol Myers Squibb also has an important division of oncology.

Factual coreconfirmed by several independent voices

Insufficient core: not enough independent confirmations to retain a shared fact.

Reported detailssecondary facts, each attributed to its source

BMS, headquartered in Princeton and known for its cancer treatments, is worth $133bn.
according to The Guardian - Business
AstraZeneca, run by longtime chief executive Pascal Soriot, is the second-biggest listed company in the UK, with a market value of nearly £196bn.
according to The Guardian - Business
Both companies have been assessing the possible alliance in recent months and contacts may lead to an agreement , although it is also possible that the project will not advance, the FT added.
according to Observador
AstraZeneca has grown to become a “giant” in the pharmaceutical sector with a leading portfolio of oncology medicines, but Bristol Myers Squibb also has an important division of oncology.
according to Observador